Pharmacy Daily | Another GSK dosing denial

GLAXOSMITHKLINE’S Children’s Panadol 1-5 years suspension remains in limbo, after the Federal Court this week granted another temporary injunction against an alternative dosing system. GSK was forced to remove the product from pharmacy shelves some weeks ago, after rival Reckitt Benckiser brought a case against the company alleging that the syringe-based dispenser used on the Panadol product infringed a patent on RB’s dosing system for Nurofen for Children (PD 07 Jun). In this latest development, a decision rendered on Wednesday granted the injunction against an alternative syringe-based dosing device for use with the new Children’s Panadol 1-5 years. GSK said it’s now “considering its options” pending final court hearings over the matters. The company noted that the legal proceedings relate only to the new Children’s Panadol 1-5 years suspension, with Children’s Panadol Baby Drops, Children’s Panadol 5-12 years Elixir and the new Children’s Panadol 5-12 years suspensions not impacted. GSK reassured customers that there is no safety risk associated with the new Children’s Panadol range, adding that it’s “using its best endeavours to ensure Childrens Panadol 1-5 years suspension product will be available to customers as soon as possible”.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jul 13
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jul 13